Volume 104, Issue 10 pp. 3510-3523
RESEARCH ARTICLE

Development and In Vitro Evaluation of Vitamin E-Enriched Nanoemulsion Vehicles Loaded with Genistein for Chemoprevention Against UVB-Induced Skin Damage

Bill Brownlow

Bill Brownlow

Department of Pharmaceutical Sciences, College of Pharmacy-Glendale, Midwestern University, Glendale, Arizona, 85308

Search for more papers by this author
Vinay J. Nagaraj

Vinay J. Nagaraj

Department of Biochemistry, Midwestern University, Glendale, Arizona, 85308

Search for more papers by this author
Amy Nayel

Amy Nayel

Midwestern University, College of Pharmacy-Glendale, Glendale, Arizona, 85308

Search for more papers by this author
Megha Joshi

Megha Joshi

Arizona College of Osteopathic Medicine, Midwestern University, Glendale, Arizona, 85308

Search for more papers by this author
Tamer Elbayoumi

Corresponding Author

Tamer Elbayoumi

Department of Pharmaceutical Sciences, College of Pharmacy-Glendale, Midwestern University, Glendale, Arizona, 85308

Telephone: +623-572-3592; Fax: +623-572-3565, E-mail: [email protected]Search for more papers by this author
First published: 24 June 2015
Citations: 8

Abstract

There is a great need for effective protection against cutaneous pathologies arising from chronic exposure to harmful solar UVB radiations. A promising pharmaceutical strategy to improve the efficacy of chemotherapeutic/preventative natural compounds (e.g., soy isoflavone Genistein, Gen) is to enhance their dermal delivery using nanoemulsion (NE) formulations. This report investigates the development of nanoemulsified tocotrienol(T3)-rich fraction of red palm oil (Tocomin®), to yield an optimal NE delivery system for dermal photoprotection (z-average size <150 nm, ζ-potential ≈ −30 mV, polydispersity index < 0.25). Physicochemical characterization and photostability studies indicate NE formulations utilizing surfactant mixture (Smix) of Solutol® HS-15 (SHS15) blended with vitamin E TPGS (TPGS) as cosurfactant was significantly superior to formulations that utilized Lutrol® F68 (LF68) as the cosurfactant. A ratio of 60:40 of SHS15–TPGS-NE was further identified as lead Tocomin® NE topical platform using in vitro pharmaceutical skin reactivity studies that assess cutaneous irritancy and cytotoxicity. Prototype Tocomin® NE loaded with the antiphotocarcinogenic molecule Gen (Gen-Tocomin® NE) showed slow-release profile in both liquid and cream forms. Gen-Tocomin® NE also showed excellent biocompatibility, and provided substantial UVB protection to cultured subcutaneous L929 fibroblasts, indicating the great potential of our Tocomin® NE warranting further prototype development as topical pharmaceutical platform for skin photoprotection applications. © 2015 Wiley Periodicals, Inc. and the American Pharmacists Association J Pharm Sci 104:3510–3523, 2015

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.